MVM was founded in 1997 and manages several funds. MVM's latest fund totals more than $200 million. MVM has a global perspective on healthcare and maintains offices in Boston and London.
MVM invests broadly across the healthcare sector, including biotechnology, specialty pharmaceuticals, medical technology, diagnostics, life science tools, consumer healthcare, veterinary medicine, healthcare services, and digital health.
Providence Medical Technology, Inc., an innovator in tissue-sparing, cervical-fusion technology, has announced the closing of $10.5 million in new equity financing for the company.
Wilson Therapeutics AB has announced that the Phase II study of WTX101 (bis-choline tetrathiomolybdate; Decuperate®), an investigational first in class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, met its primary endpoint.